TCGA-AN-A0XW-01A-11R-A109-07
— · C
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- C
- subtype
- C
- overall_survival_months
- 6
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.600
- ALLOGRAFT_REJECTION+0.560
- INTERFERON_GAMMA_RESPONSE+0.520
- INTERFERON_ALPHA_RESPONSE+0.460
- IL6_JAK_STAT3_SIGNALING+0.450
- INFLAMMATORY_RESPONSE+0.440
- KRAS_SIGNALING_UP+0.390
- TNFA_SIGNALING_VIA_NFKB+0.390
- PANCREAS_BETA_CELLS+0.360
- COAGULATION+0.350
Top 10 suppressed
- MYC_TARGETS_V2-0.450
- DNA_REPAIR-0.290
- OXIDATIVE_PHOSPHORYLATION-0.280
- WNT_BETA_CATENIN_SIGNALING-0.280
- UNFOLDED_PROTEIN_RESPONSE-0.270
- FATTY_ACID_METABOLISM-0.230
- MYC_TARGETS_V1-0.190
- ADIPOGENESIS-0.170
- SPERMATOGENESIS-0.020
- HEME_METABOLISM+0.000
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
7 twins match this tumor's tissue · 3 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR10900576 | — | — | 0.903 |
| 2 | BS_PRAEF32W | EPN | Posterior Fossa EPN | 0.873 |
| 3 | TCGA-44-6779-01A-11R-1858-07 | — | cohortA1 | 0.872 |
| 4 | TCGA-GV-A3QG-01A-11R-A220-07 | — | — | 0.871 |
| 5 | s0122206 | — | — | 0.869 |
| 6 | SRR934980 | — | — | 0.867 |
| 7 | SRR10899973 | — | — | 0.866 |
| 8 | c55bb20b-c929-42e2-be7f-8b1da7bee953 | — | — | 0.865 |
| 9 | BS_593HEWBF | Ganglioglioma | — | 0.860 |
| 10 | MDT-AP-2029 | Med | Medulloblastoma | 0.860 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 40 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.600 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.560 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.520 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.460 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.450 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.440 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.390 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.390 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.360 | Cobimetinib | — uncovered |
| COAGULATION | 0.350 | Binimetinib | — uncovered |
| COMPLEMENT | 0.350 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.350 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.340 | Remibrutinib | — uncovered |
| APOPTOSIS | 0.320 | Idelalisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.320 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.310 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.290 | Idelalisib | — uncovered |
| APICAL_JUNCTION | 0.270 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.260 | Temsirolimus | — uncovered |
| MTORC1_SIGNALING | 0.260 | Inavolisib | — uncovered |